Inclusion Criteria:~* Male or female patients aged 50 and above at the time of signing the Informed Consent
Form~* Patients who can understand and provide written informed consent (assent)~* Patients who have a
diagnosis of probable mild Alzheimer's Disease(AD) according to the National Institute of Neurological and
Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
criteria within one year of the start of treatment~* Patients who have an MMSE Score of 20 to 24 at screening~*
Patients who have a Clinical Dementia Rating (CDR)-Global Score of 0.5 to 1 at baseline~* Patients who have any
FDA-approved AD medication (donepezil, galantamine, memantine, rivastigmine or any combination) since their AD
diagnosis receiving a stable dose of medical teratment for at least 12 weeks prior to Screening and were to
stay on a stable dose during the study~* Patients who have one (or more) identified adult caregiver (study
partner) who is able to read, understand, and speak the designated language at the study site; who either lives
with the subject or sees the subject for ≥2 hours/day ≥4 days/week; and who agrees to accompany the subject to
each study visit and to participate in the subject's clinical assessments~* Patients who have a diagnosis of
probable mild AD according to Amyloid PET scan at screening~
